T60ZGSZ — APS Tirzepatide
Vendor COAAPS | Tirzepatide, last activity 3 weeks ago
5 related batch concerns
Get notified when a lab result is posted, a group test forms, or this batch is flagged by the community.
Test Results
The label says 60 mg. Janoshik weighed 65.3 mg — 9% more than the label. Your dose depends on what is really in the vial, so the steps below use the measured amount.
Draw
18 units
on a U-100 insulin syringe, for 6 mg
Going by the label you would draw 20 units — which from this vial is actually 6.53 mg, not 6 mg.
- The vial holds dry powder: 65.3 mg of Tirzepatide, as weighed.
- Water spreads that powder evenly through the liquid: 65.3 mg ÷ 2 ml = 32.6 mg per ml.
- An insulin syringe counts in units, 100 to the ml, so each unit carries 326 mcg.
- Your dose divided by that: 6 mg ÷ 326 mcg = 18 units.
The water changes how many units a dose takes, never how much peptide you get. Twice the water means twice the units for the same dose. What sets the dose is how much is in the vial — which is why the measured amount matters.
Arithmetic, not medical advice. Assumes a U-100 syringe and that the powder fully dissolves. The figure is from the vial that was tested; yours is from the same lot but was not weighed itself.
Related batches
5 of 5 tested
also APS
This batch is getting roughly three times the usual attention for its age, with three positive reports and three…
Retatrutide, same vendor
An independent test found endotoxin at 1,437.86 EU/vial, far exceeding the 10 EU/vial working limit, while the vendor's…
GYC/GGpeps
Endotoxin levels have exceeded the 10 EU/vial working limit in two independent Janoshik tests (17.116 and 47.923…
also APS
First seen more than three months ago and drawing unusually little attention for its age
also APS
An independent Janoshik test and the vendor's own certificate both confirm purity above 99.7%, with measured fill…
Community Intelligence
- 1 concern report involving REPTN
- 1 concern report involving REPTN-1
- 2 concern reports involving PYQI
- 1 concern report involving 2026061030
- 2 concern reports involving SN26XY-1-02
Reported against other APS Tirzepatide batches, not this one.
Activity
No community activity tracked yet.
Vendor
APS